MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Bevacizumab (Avastatin)

A review of bevacizumab in the treatment of malignant pleural mesothelioma

Future Oncology 2017 September [Epub ahead of print] [Link] Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, […]

Comments Off on A review of bevacizumab in the treatment of malignant pleural mesothelioma

The Effect of Aquaporin 1-Inhibition on Vasculogenic Mimicry in Malignant Mesothelioma

International Journal of Molecular Services 2017 November [Link] Pulford E, McEvoy J, Hocking A, Prabhakaran S, Griggs K, Klebe S Abstract Malignant mesothelioma (MM) is an aggressive malignancy of the serosal membranes, with poor overall survival and quality of life. Limited targeted treatment strategies exist due to restricted knowledge of pathogenic pathways. Vasculogenic mimicry (VM) […]

Comments Off on The Effect of Aquaporin 1-Inhibition on Vasculogenic Mimicry in Malignant Mesothelioma

Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial

Lung Cancer 2017 August [Epub 2017 May 12] [Link] Zhan M, Zheng H, Xu T, Yang Y, Li Q Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is a rare malignancy, and pemetrexed/cisplatin (PC) is the gold standard first-line regime. This study evaluated the cost-effectiveness of the addition of bevacizumab to PC (with maintenance bevacizumab) for unresectable […]

Comments Off on Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Expert Opinion of Investigational Drugs 2017 July 6 [Epub ahead of print] [Link] Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L Abstract INTRODUCTION: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to […]

Comments Off on Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

Onco Targets and Therapy 2017 April [Link] Levin PA, Dowell JE Abstract Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as important players […]

Comments Off on Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

Expert Review of Anticancer Therapy 2016 October 4 [Epub ahead of print] [Link] Chia PL, Russell P, Scott AM, John T Abstract INTRODUCTION: Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other serosal membranes originating from mesothelial cells that, despite decades of research, continues to have limited therapeutic options and is associated […]

Comments Off on Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016

Journal of the National Comprehensive Cancer Network 2016 July 14 [Link] Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins […]

Comments Off on NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016

MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients

Genomics Data 2016 June 20 [Link] Lin RC, Kirschner MB, Cheng YY, van Zandwijk N, Reid G Abstract Malignant pleural mesothelioma (MPM) is a tumor originating in the mesothelium, the membrane lining the thoracic cavities, and is induced by exposure to asbestos. Australia suffers one of the world’s highest rates of MPM and the incidence […]

Comments Off on MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients

Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells

Oncogene 2016 June 27 [Epub ahead of print] [Link] Eguchi R, Nakano T, Wakabayashi I. Abstract Malignant mesothelioma is an aggressive tumor arising from the mesothelial cells of serous membranes and is associated with tumor angiogenesis, which is a prerequisite for tumor progression. Vascular endothelial growth factors (VEGFs) including VEGF-A have a crucial role in […]

Comments Off on Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Lancet 2015 December 21 [Epub ahead of print] [Link] Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup […]

Comments Off on Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial